AI Empowering Life Sciences and Advancing Human Health and Longevity
Pharmolix Inc. focuses on developing foundational models and intelligent agents for the life sciences. Established in June 2023, the company originated from the Artificial Intelligence Research Institute (AIR) of Tsinghua University, founded by Professor Zaiqing Nie. Pharmolix Inc. has launched ChatDD, the world’s first intelligent agent for biopharmaceutical R&D, and other AI models for biomedicine. Pharmolix Inc. was recognized as one of the Top 10 ScienceAI Leading Enterprises. Pharmolix Inc. currently use its intelligent platforms for discovery and development of innovation in biologic drugs. By deploying its multi-objective, all-atom protein design intelligent agent, the company has built a next-generation AI-driven R&D platform integrated with a closed-loop wet-lab validation system, significantly enhancing the precision, efficiency, and diversity of protein drug design.
The company collaborates closely with global pharmaceutical and biotech leaders such as Fosun Pharma, Gilead, AstraZeneca, Asymchem, and XtalPi, translating cutting-edge multimodal biopharmaceutical large-model research into real-world applications that accelerate the intelligent transformation of the pharmaceutical industry. Pharmolix Inc. has also established deep partnerships with dozens of leading biopharmaceutical companies, hospitals, and research institutions.